LORBRENA

This brand name is authorized in United States. It is also authorized in Brazil, Canada, Ecuador, Japan.

Active ingredients

The drug LORBRENA contains one active pharmaceutical ingredient (API):

1	Lorlatinib UNII OSP71S83EU - LORLATINIB
	Lorlatinib is a selective, adenosine triphosphate (ATP)-competitive inhibitor of ALK and c-ros oncogene 1 (ROS1) tyrosine kinases.
	Read more about Lorlatinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LORBRENA Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01ED05		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01ED Anaplastic lymphoma kinase (ALK) inhibitors
Discover more medicines within L01ED05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	522720080089407, 522720080089507
CA	Health Products and Food Branch	02485966, 02485974
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	6764-MEE-1121, 6789-MEE-1221
JP	医薬品医療機器総合機構	4291055F1020, 4291055F2027
US	FDA, National Drug Code	0069-0227, 0069-0231